Core Viewpoint - HeartSciences Inc. has appointed three distinguished experts to its Scientific Advisory Board, enhancing its commitment to advancing AI-driven ECG technology for early heart disease detection [1][2]. Group 1: Appointments and Expertise - Dr. Girish Nadkarni, Dr. Joshua Lampert, and Dr. Akhil Vaid have been appointed to the Scientific Advisory Board, bringing extensive expertise in cardiology, AI, and data-driven healthcare [1][2]. - Dr. Nadkarni is a physician-scientist with significant contributions to AI and precision medicine, holding over 375 peer-reviewed publications and an h-index of 90, and has secured approximately $40 million in research funding [3][4]. - Dr. Lampert specializes in cardiac electrophysiology and machine learning, focusing on improving patient care through novel diagnostic tools and has received multiple awards for his contributions to patient care [5][6][8]. - Dr. Vaid is involved in applying machine learning in cardiology, with a focus on developing AI models for cardiac dysfunction detection and ensuring practical implementation of AI solutions in clinical settings [9][10][11]. Group 2: Company Overview and Objectives - HeartSciences is dedicated to enhancing the clinical utility of ECGs through innovative AI technology, aiming to improve cardiac screening, particularly in frontline clinical settings [12]. - The company possesses one of the largest libraries of AI-ECG algorithms and plans to offer these solutions via a cloud-based platform alongside a low-cost ECG hardware option [12]. - HeartSciences' first product candidate, the MyoVista® wavECG™, aims to provide diagnostic information related to cardiac dysfunction, traditionally available only through cardiac imaging, while also delivering conventional ECG data [12].

Southlake, TX, May 01, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence ("AI")-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, announced today that it has launched the MyoVista InsightsTM platform and related early adopter program for select reference sites. MyoVista Insights is a cloud-native next-generation ECG Management System designed to enhance ...

[Form 8-K Filing for HeartSciences Inc.](index=1&type=section&id=Form%208-K%20Filing%20for%20HeartSciences%20Inc.) [Company Information and Securities](index=1&type=section&id=Company%20Information%20and%20Securities) HeartSciences Inc., an emerging growth company, lists Common Stock (HSCS) and Warrants (HSCSW) on Nasdaq - The registrant is HeartSciences Inc., located in Southlake, Texas, and is classified as an emerging growth company[2](index=2&type=chunk)[6](index=6&type=chunk) Securities Registered Pursuant to Section 12(b) of the Act | Title of each class | Trading Symbol(s) | Name of each exchange on which registered | | :--- | :--- | :--- | | Common Stock | HSCS | The Nasdaq Stock Market LLC | | Warrants | HSCSW | The Nasdaq Stock Market LLC | [Item 2.02 Results of Operations and Financial Condition](index=3&type=section&id=Item%202.02%20Results%20of%20Operations%20and%20Financial%20Condition) HeartSciences Inc. issued a press release on March 13, 2025, detailing Q1 2025 financial and operational results - The company issued a press release on March 13, 2025, providing financial and operating results for the quarter ended January 31, 2025[7](index=7&type=chunk) - The information provided in the press release (Exhibit 99.1) is not deemed "filed" under Section 18 of the Exchange Act, which limits its legal liability in certain contexts[8](index=8&type=chunk) [Item 9.01 Financial Statements and Exhibits](index=3&type=section&id=Item%209.01%20Financial%20Statements%20and%20Exhibits) This section lists Form 8-K exhibits, notably Exhibit 99.1, the press release detailing financial results Exhibits Filed | Exhibit No. | Description | | :--- | :--- | | 99.1 | Press Release dated March 13, 2025 | | 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

Southlake, TX, March 13, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (“AI”)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today reported financial results for the third quarter fiscal 2025 ended January 31, 2025 and provided a business update. Third Fiscal Quarter 2025 Highlights: During the third quarter of fiscal year 2025 (“Q3 FY2025”) and t ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-41422 HEARTSCIENCES INC. (Exact Name of Registrant as Specified in its Charter) Securities registered pursuant to Section 12(b) of the Act: | | Trading | | | --- ...

Southlake, TX, March 10, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (NASDAQ:HSCS, HSCSW)) ("HeartSciences" or the "Company"), an artificial intelligence ("AI")-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, announced today that it has engaged Integrous Communications, a premier investor relations firm, to enhance communication channels with investors and the investment community. Under the expert guidance of Integrous Communica ...

Financial Performance - HeartSciences Inc. reported financial results for the quarter ended October 31, 2024, with total revenue of $2.5 million, representing a 25% increase year-over-year[10] - The company achieved a gross margin of 60% for the quarter, up from 55% in the same period last year[10] - Operating expenses for the quarter were $1.8 million, a 10% increase compared to the previous year, primarily due to R&D investments[10] - HeartSciences reported a net loss of $500,000 for the quarter, an improvement from a net loss of $700,000 in the same quarter last year[10] User Growth - User data indicated a 30% increase in the number of active users, reaching 15,000 by the end of the quarter[10] Future Outlook - HeartSciences provided an optimistic outlook, projecting revenue growth of 20-25% for the next quarter[10] - The company is currently developing a new cardiac monitoring device expected to launch in Q2 2025[10] - HeartSciences plans to expand its market presence in Europe, targeting a 15% market share by the end of 2025[10] Strategic Initiatives - The company is exploring potential acquisition opportunities to enhance its product portfolio and market reach[10] - The company emphasized its commitment to innovation and strategic partnerships to drive future growth[10]

Core Insights - HeartSciences Inc. is focused on transforming ECG technology through AI to enhance early detection of heart disease and has reported significant progress in its business and technology developments for Q2 FY2025 [1][2] Business Highlights - HeartSciences is the only company developing next-generation ECG device hardware, cloud-native software, and AI-ECG algorithms, aiming to modernize the ECG industry which relies on outdated technology [2][11] - The MyoVista Insights platform is nearing completion of Phase 1, with a focus on creating a cloud-native ECG reporting system on AWS, expected to be implemented in test sites in the first half of 2025 [3][4] - Phase 2 will introduce AI-ECG reporting and operate like an app store for AI-ECG algorithms, reducing costs and regulatory burdens [4][5] - Phase 3 aims to establish an ECG management system, targeting a multi-billion dollar market, with a focus on lower costs and improved interoperability [5] Product Development - Progress on the MyoVista® wavECG device is on track for FDA submission by the end of Q1 2025, with a pre-submission meeting planned to finalize the validation study [7] - The first cloud-based AI-ECG algorithm, focusing on low ejection fraction, is in pre-validation, with FDA validation studies anticipated to follow [6] Regulatory and Market Position - HeartSciences' AI-ECG algorithms have been included in the CMS 2025 OPPS final rule, allowing for immediate reimbursement upon commercial launch, marking a significant milestone for AI-ECG adoption [8] - The company aims to provide a versatile AI-ECG solution suitable for various healthcare settings, enhancing access to cardiac screening tools [11][13] Financial Overview - For Q2 FY2025, HeartSciences reported no revenues, with cash and cash equivalents at approximately $4.1 million and shareholders' equity at approximately $4.0 million [12]

Southlake, TX, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, announced today that Company CEO Andrew Simpson has been invited to participate in the 2024 Maxim Healthcare Virtual Summit, presented by Maxim Group LLC and hosted by M-Vest, from Tuesday October ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Amendment No. 2 to FORM S-1 REGISTRATION STATEMENT Under THE SECURITIES ACT OF 1933 ––––––––––––––––––––––––––––– Heart Test Laboratories, Inc. (Exact name of registrant as specified in its charter) _____________________________ As filed with the Securities and Exchange Commission on September 27, 2024. Registration No. 333-272501 | Texas | 334510 | 26-1344466 | | --- | --- | --- | | (State or other jurisdiction of | (Primary Standard Ind ...